AbbVie 'Disagrees' With NICE's Draft Rejection Of Venclyxto For CLL
Executive Summary
NICE has rejected AbbVie's BCL-2 inhibitor on grounds that evidence presented by the drug maker didn't adequately prove Venclyxto's clinical effectiveness, nor that the cancer product would be value for money.